UTHR logo

UNITED THERAPEUTICS CORP

UTHRNASDAQ
πŸ† #439 by market capEarnings Feb 24US Equity
β€”β€”
Quote unavailable
πŸ””
Track UTHR
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$25.68B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
1.9%
Slowing
πŸ“ŠGross Margin
86.3%
High
πŸ’΅FCF Margin
27.2%
Strong
βš–οΈP/S Ratio
7.2x
Fair
Otter Score
76
Strong
No chart data available for UTHR.

Trading Snapshot

Day Range
β€”
52-Week Range
$455.63 – $614.23
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
42.9M
Next Earnings
2027-02-24

Fundamentals Snapshot

Annual Revenue
$3.18B
Last Q Revenue
$833M
P/E Ratio
18.7
P/S Ratio
7.2x
EPS (TTM)
$26.51
Dividend Yield
β€”
Dilution (1yr)
βˆ’1.6%
UTHR logo

UNITED THERAPEUTICS CORP

UTHR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3.2Bβ–² +10.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
87.9%β–Ό βˆ’1.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$1.5Bβ–² +10.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.0Bβ–Ό βˆ’3.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
47.9Mβ–Ό βˆ’1.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$1.5Bβ–² +$122M YoY
StockOtter Β· stockotter.space

About UNITED THERAPEUTICS CORP

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

Business WireΒ·2d ago

United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidneyβ„’ in Patients with End-Stage Renal Disease

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the first clinical xenotransplant in its EXTEND study of t

Defense WorldΒ·3d ago

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $5,627,990.00 in Stock

United Therapeutics Corporation (NASDAQ: UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Friday, November 13th. The shares were sold at an average price of $

Defense WorldΒ·4d ago

Commonwealth Equity Services LLC Purchases 1,695 Shares of United Therapeutics Corporation $UTHR

Commonwealth Equity Services LLC lifted its position in United Therapeutics Corporation (NASDAQ: UTHR) by 32.6% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Comm

Seeking AlphaΒ·5d ago

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

United Therapeutics Corporation (UTHR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

MarketBeatΒ·5d ago

United Therapeutics Prepares for TYVASO Expansion After $833 Million Quarter

United Therapeutics NASDAQ: UTHR is preparing for a potential expansion of its TYVASO franchise into idiopathic pulmonary fibrosis, while its executives pointed to strong third-quarter sales and a pipeline of regulatory

Zacks Investment ResearchΒ·6d ago

SGIOY or UTHR: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical - Drugs sector might want to consider either Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) or United Therapeutics (UTHR).